An official website of the United States government
A Study of ZW251 in Participants With Advanced Solid Tumors
Trial Status: active
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting
glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including
hepatocellular carcinoma (HCC).
Inclusion Criteria
Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or metastatic disease. Noninvasive methods may be used to confirm diagnosis
Measurable disease per RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
Liver function status of Child-Pugh Class A
Adequate organ function
Exclusion Criteria
Known additional malignancy that is progressing or that has required active treatment within the last year
History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy
Portal vein thrombosis within 3 months prior to Cycle 1 Day 1 that require coagulation therapy or is not stable
Known gastrointestinal bleeding within 3 months
Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease
Additional locations may be listed on ClinicalTrials.gov for NCT07164313.
